M&A Deal Summary |
|
|---|---|
| Date | 2023-12-19 |
| Target | VIO Chemicals |
| Sector | Life Science |
| Buyer(s) | Biosynth |
| Deal Type | Add-on Acquisition |
SEARCH BY
Biosynth is a fully hybrid research products, life sciences reagents and custom synthesis and manufacturing services company with global research, manufacturing and distribution facilities. They are the supplier of choice for many in the pharmaceutical, life science, food, agrochemical, cosmetic and diagnostic sectors and manufacture and source a vast range of chemical and biochemical products. Biosynth was formed in 1965 and is based in St. Gallen, Switzerland.
| DEAL STATS | # |
|---|---|
| Overall | 8 of 8 |
| Sector: Life Science M&A | 7 of 7 |
| Type: Add-on Acquisition M&A Deals | 8 of 8 |
| Country: Switzerland M&A | 1 of 1 |
| Year: 2023 M&A | 4 of 4 |
| DATE | TARGET | DEAL TYPE | VALUE |
|---|---|---|---|
| 2023-09-25 |
Pepceuticals
Enderby, United Kingdom Pepceuticals is a specialist British manufacturer of synthetic peptides, dedicated to supplying the Life Science industry with high-quality custom peptides. The company has developed technologies that allow the preparation of complex peptide molecules. Operating from a purpose-built manufacturing facility, it provides a comprehensive drug development program to support all aspects of peptide manufacture. This includes delivery of peptides manufactured under cGMP from milligram to kilogram quantities. Pepceuticals is based in Enderby, United Kingdom. |
Buy | - |
